Company Snapshot: Prothena Corporation
Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinsons disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.
- Aug 15 2017 Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting
- Aug 8 2017 Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update
- Aug 1 2017 Prothena to Report Second Quarter 2017 Financial Results on August 8
- Jul 5 2017 Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease